Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,050 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Not applicable Interventional Results available

NAD+ and Exercise in FA

NCT04192136
View directory record Official record
Conditions
Friedreich Ataxia 1
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Febuxostat in Participants With Gout

NCT00430248
View directory record Official record
Conditions
Gout
Interventions
Febuxostat, Allopurinol
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
258
States / cities
Birmingham, Alabama • Hoover, Alabama • Hueytown, Alabama + 255 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 28, 2026, 11:42 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

NCT01807026
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

NCT05893043
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GSBR-1290, Placebo
Drug · Other
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 28, 2026, 11:42 PM EDT
Recruiting Phase 2 Interventional

2-HOBA in Systemic Lupus Erythematosus

NCT07225543
View directory record Official record
Conditions
Systemic Lupus Erthematosus (SLE)
Interventions
2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cognitive Remediation With D-Cycloserine

NCT01399866
View directory record Official record
Conditions
Smoking Cessation
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 28, 2026, 11:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

NCT02607228
View directory record Official record
Conditions
Metastatic Castrate-Resistant Prostate Cancer
Interventions
Alobresib, Enzalutamide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Opioid Modulation and Neural Reward Activation in Healthy Adults

NCT04854551
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use, Unspecified
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 28, 2026, 11:42 PM EDT
Not listed Not applicable Interventional

Micronutrients as Adjunctive Treatment for Bipolar Disorder

NCT03541031
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Micronutrient & Fish oil, Olive oil & Safflower oil
Dietary Supplement
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Not applicable Interventional

Palm Tocotrienols in Chronic Hemodialysis (USA)

NCT02358967
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
TRF (Tocotrienol-rich-fraction), Placebo
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 28, 2026, 11:42 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Nutritional Preconditioning on the Patient's Outcomes After Surgery

NCT03692507
View directory record Official record
Conditions
Major Abdominal/GI Surgery
Interventions
HMB, Protein and HMB, ERAS
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 28, 2026, 11:42 PM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

NCT03977207
View directory record Official record
Conditions
Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
Interventions
Levothyroxine Sodium, Placebos
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 28, 2026, 11:42 PM EDT
Not listed Phase 1 Interventional

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

NCT04990739
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
MTB-9655
Drug
Lead sponsor
MetaboMed Inc
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 28, 2026, 11:42 PM EDT
Not listed Phase 4 Interventional

Solriamfetol in Binge Eating Disorder

NCT04602936
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Class 3 Biowaivers

NCT01010698
View directory record Official record
Conditions
Healthy
Interventions
cimetidine (or acyclovir)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 4 Interventional Results available

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

NCT02917031
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Heart Failure
Interventions
Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Torrance, California • Upland, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Not applicable Interventional

REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID

NCT05840237
View directory record Official record
Conditions
Post-COVID-19 Syndrome, Fatigue Syndrome, Chronic
Interventions
Anhydrous Enol-Oxaloacetate, a "Medical Food", White Rice Flour
Other
Lead sponsor
Terra Biological LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

NCT03302845
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 28, 2026, 11:42 PM EDT
Completed Phase 2 Interventional Results available

ALS Reversals - Lunasin Regimen

NCT02709330
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Lunasin Regimen, Historical control
Drug · Other
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 28, 2026, 11:42 PM EDT